GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients

References

• Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic Steatohepatitis: mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–438.
   PubMed Web of Science ®Google Scholar
• Brown GT, Kleiner DE. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism. 2016;65(8):1080–1086. doi: 10.1016/j.metabol.2015.11.008
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for Nonalcoholic Steatohepatitis. Hepatology. 2011;54:344–353. doi: 10.1002/hep.24376
   PubMedGoogle Scholar
• Keerl C, Bernsmeier C Erhöhte Leberwerte – Zufallsbefund in der Hausarztpraxis. Ther Umsch 2020;77:371–378. doi: 10.1024/0040-5930/a001206
   PubMedGoogle Scholar
• Jang W, Song JS Non-invasive imaging methods to evaluate non-alcoholic fatty liver disease with fat quantification: a review. Diagn (Basel). 2023;13(11):1852. doi: 10.3390/diagnostics13111852
   PubMedGoogle Scholar
• Fetzer DT, Pierce TT, Robbin ML, et al. US quantification of liver fat: past, present, and future. Radiographics. 2023;43:e220178. doi: 10.1148/rg.220178
   PubMed Web of Science ®Google Scholar
• Hansen HH, Pors S, Andersen MW, et al. Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis. Sci Rep. 2023;13:23056. doi: 10.1038/s41598-023-50328-5
   PubMed Web of Science ®Google Scholar
• Tanaka M, Kaji K, Nishimura N, et al. Blockade of Angiotensin II Modulates Insulin-like Growth Factor 1-Mediated Skeletal Muscle Homeostasis in Experimental Steatohepatitis. Biochim Biophys Acta Mol Cell Res. 2024;1871:119649. doi: 10.1016/j.bbamcr.2023.119649
   PubMed Web of Science ®Google Scholar
• Younossi Z, Aggarwal P, Shrestha I, et al. The burden of Non-Alcoholic Steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes. JHEP Rep. 2022;4(9):100525. doi: 10.1016/j.jhepr.2022.100525
   PubMedGoogle Scholar
• Wang X, He Q, Zhou C, et al. Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH Development. Immunity. 2023;56:58–77.e11. doi: 10.1016/j.immuni.2022.11.013
   PubMed Web of Science ®Google Scholar
• Qin S, Chen J, Zhong K, et al. Could cyclosiversioside F serve as a dietary supplement to prevent obesity and relevant disorders? Int J Mol Sci. 2023;24(18):13762. doi: 10.3390/ijms241813762
   Web of Science ®Google Scholar
• Adeghate E, Schattner P, Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci. 2006;1084(1):1–29. doi: 10.1196/annals.1372.029
   PubMedGoogle Scholar
• Lotfy M, Adeghate J, Kalasz H, et al. Chronic complications of diabetes mellitus: a mini review. Curr Diabetes Rev. 2017;13:3–10. doi: 10.2174/1573399812666151016101622
   PubMed Web of Science ®Google Scholar
• Huang X-L, He Y, Ji L-L, et al. Hepatoprotective potential of isoquercitrin against type 2 diabetes-induced hepatic injury in rats. Oncotarget. 2017;8:101545–101559. doi: 10.18632/oncotarget.21074
   PubMedGoogle Scholar
• Farid MM, Aboul Naser AF, Salem MM, et al. Chemical compositions of Commiphora opobalsamum stem bark to alleviate liver complications in streptozotocin-induced diabetes in rats: role of oxidative stress and DNA damage. Biomarkers. 2022;27:671–683. doi: 10.1080/1354750X.2022.2099015
   PubMed Web of Science ®Google Scholar
• Dugbartey GJ, Alornyo KK, Adams I, et al. Targeting hepatic sulfane Sulfur/Hydrogen sulfide signaling pathway with α-Lipoic Acid to prevent diabetes-induced liver injury via upregulating hepatic CSE/3-MST expression. Diabetol Metab Syndr. 2022;14:148. doi: 10.1186/s13098-022-00921-x
   PubMed Web of Science ®Google Scholar
• Dokumacioglu E, Iskender H, Musmul A. Effect of hesperidin treatment on α-Klotho/FGF-23 pathway in rats with experimentally-induced diabetes. Biomed Pharmacother. 2019;109:1206–1210. doi: 10.1016/j.biopha.2018.10.192
   PubMed Web of Science ®Google Scholar
• Hernández-Espinosa D, Ayala I, Castells MT, et al. Intracellular retention of hepatic serpins caused by severe hyperlipidemia. Liver Int. 2006;26:708–715. doi: 10.1111/j.1478-3231.2006.01274.x
   PubMed Web of Science ®Google Scholar
• Ahmed S, Khan RA, Jamil S. Anti hyperlipidemic and hepatoprotective effects of native date fruit variety ”aseel” (Phoenix dactylifera). Pak J Pharm Sci. 2016;29:1945–1950.
   PubMed Web of Science ®Google Scholar
• Aldossari KK The epidemiology and characteristics of patients with diabetes with or without NASH: a systematic review. Afr Health Sci 2023;23:509–518. doi: 10.4314/ahs.v23i2.59
   PubMed Web of Science ®Google Scholar
• Raverdy V, Chatelain E, Lasailly G, et al. Combining diabetes, sex, and menopause as meaningful clinical features associated with NASH and liver fibrosis in individuals with class II and III obesity: a retrospective cohort study. Obesity (Silver Spring). 2023;31:3066–3076. doi: 10.1002/oby.23904
   PubMed Web of Science ®Google Scholar
• Eng PC, Forlano R, Tan T, et al. Non-alcoholic fatty liver disease in women – Current knowledge and emerging concepts. JHEP Rep. 2023;5:100835. doi: 10.1016/j.jhepr.2023.100835
   PubMedGoogle Scholar
• Landete P, Fernández-García CE, Aldave-Orzaiz B, et al. Increased oxygen desaturation time during sleep is a risk factor for NASH in patients with obstructive sleep apnea: a prospective cohort study. Front Med. 2022;9:808417. doi: 10.3389/fmed.2022.808417
   Web of Science ®Google Scholar
• Grillo PM, Punaro GR, Elias MC, et al. Obstructive sleep apnea syndrome risk in patients with non-alcoholic fatty liver disease is associated with obesity and presence of NASH. Arq Gastroenterol. 2022;59(2):251–256. doi: 10.1590/S0004-2803.202202000-45
   PubMedGoogle Scholar
• Wong VW-S, Ekstedt M, Wong GL-H, et al. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79:842–852. doi: 10.1016/j.jhep.2023.04.036
   PubMed Web of Science ®Google Scholar
• Lindén D, Romeo S. Therapeutic opportunities for the treatment of NASH with genetically validated targets. J Hepatol. 2023;79:1056–1064. doi: 10.1016/j.jhep.2023.05.007
   PubMed Web of Science ®Google Scholar
• Kozono M, Uto H, Ibusuki R, et al. Antihypertensive therapy improves insulin resistance and serum levels of interleukin-6 and −10 in spontaneously hypertensive rats with steatohepatitis. Mol Med Rep. 2016;14(6):5385–5394. doi: 10.3892/mmr.2016.5875
   PubMed Web of Science ®Google Scholar
• Denk H, Abuja PM, Zatloukal K Animal models of NAFLD from the pathologist’s point of view. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2019;1865(5):929–942. doi: 10.1016/j.bbadis.2018.04.024
   PubMed Web of Science ®Google Scholar
• Chen H, Huang X, Dong M, et al. The association between Sarcopenia and diabetes: from pathophysiology mechanism to therapeutic strategy. Diabetes Metab Syndr Obes. 2023 May 30;16:1541–1554. eCollection 2023. doi: 10.2147/DMSO.S410834
   PubMed Web of Science ®Google Scholar
• Thomas JA, Kendall BJ, El-Serag HB, et al. Hepatocellular and Extrahepatic cancer risk in people with non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2024;9:159–169. doi: 10.1016/S2468-1253(23)00275-3
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016, 64(1):73–84, doi: 10.1002/hep.28431
   PubMed Web of Science ®Google Scholar
• Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69:896–904. doi: 10.1016/j.jhep.2018.05.036
   PubMed Web of Science ®Google Scholar
• Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45:600–606. doi: 10.1016/j.jhep.2006.06.013
   PubMed Web of Science ®Google Scholar
• Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158:1851–1864. doi: 10.1053/j.gastro.2020.01.052
   PubMed Web of Science ®Google Scholar
• Smail MM, Singh J, Ismail AM, et al. Cellular and biochemical mechanisms driving the susceptibility of obese subjects to covid-19 infection. In: Tappia PS, Ramjiawan B Dhalla NS. editors. Cellular and Biochemical Mechanisms of Obesity. Cham: Springer International Publishing; 2021. p. 105–118. ISBN 978-3-030-84763-0.
   Google Scholar
• Divella R, Mazzocca A, Daniele A, et al. Obesity, nonalcoholic fatty liver disease and adipocytokines network in promotion of cancer. Int J Biol Sci. 2019;15:610–616. doi: 10.7150/ijbs.29599
   PubMed Web of Science ®Google Scholar
• Mahgoub MO, Ali II, Adeghate JO, et al. An update on the molecular and cellular basis of pharmacotherapy in type 2 diabetes mellitus. Int J Mol Sci. 2023;24: doi: 10.3390/ijms24119328
   PubMed Web of Science ®Google Scholar
• Singh RM, Waqar T, Howarth FC, et al. Hyperglycemia-induced cardiac contractile dysfunction in the diabetic heart. Heart Fail Rev. 2018;23(1):37–54. doi: 10.1007/s10741-017-9663-y
   PubMed Web of Science ®Google Scholar
• Mahgoub E, Kumaraswamy SM, Kader KH, et al. Genipin attenuates cisplatin-induced nephrotoxicity by counteracting oxidative stress, inflammation, and apoptosis. Biomed Pharmacother. 2017;93:1083–1097. doi: 10.1016/j.biopha.2017.07.018
   PubMed Web of Science ®Google Scholar
• Xu J, Xia Q, Wu T, et al. Prophylactic treatment with Bacteroides Uniformis and bifidobacterium bifidum counteracts hepatic NK cell immune tolerance in nonalcoholic steatohepatitis induced by high fat diet. Gut Microbes. 2024;16:2302065. doi: 10.1080/19490976.2024.2302065
   PubMed Web of Science ®Google Scholar
• Su C, Wang J, Luo H, et al. Gut microbiota plays essential roles in Soyasaponin’s preventive bioactivities against Steatohepatitis in the methionine and choline deficient (MCD) diet-induced non-alcoholic Steatohepatitis (NASH) mice. Mol Nutr Food Res. 2024; 68(4):e2300561. doi: 10.1002/mnfr.202300561
   PubMed Web of Science ®Google Scholar
• Gruzdev SK, Podoprigora IV, Gizinger OA. Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets. Arch Microbiol. 2024;206:62. doi: 10.1007/s00203-023-03752-0
   PubMed Web of Science ®Google Scholar
• Cao P, Yue M, Cheng Y, et al. Naringenin prevents non-alcoholic steatohepatitis by modulating the host metabolome and intestinal microbiome in MCD diet-fed mice. Food Sci Nutr. 2023;11(12):7826–7840. doi: 10.1002/fsn3.3700
   PubMed Web of Science ®Google Scholar
• Basu Ray S. PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease. Adipocyte. 2019;8:201–208. doi: 10.1080/21623945.2019.1607423
   PubMed Web of Science ®Google Scholar
• Zhang H-B, Su W, Xu H, et al. HSD17B13: a potential therapeutic target for NAFLD. Front Mol Biosci. 2021;8:824776. doi: 10.3389/fmolb.2021.824776
   PubMed Web of Science ®Google Scholar
• Ting Y-W, Kong AS-Y, Zain SM, et al. Loss-of-function HSD17B13 variants, Non-Alcoholic Steatohepatitis and adverse liver outcomes: results from a multi-ethnic Asian Cohort. Clin Mol Hepatol 2021;27:486–498. doi: 10.3350/cmh.2020.0162
   PubMed Web of Science ®Google Scholar
• Amangurbanova M, Huang DQ, Loomba R. Review article: the role of HSD17B13 on global epidemiology, natural history, Pathogenesis and treatment of NAFLD. Aliment Pharmacol Ther. 2023;57:37–51. doi: 10.1111/apt.17292
   PubMed Web of Science ®Google Scholar
• Tarantino G, Sinatti G, Citro V, et al. Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression? Intern Emerg Med. 2023 Oct;18(7):1887–1895. Epub 2023 Jul 25. doi: 10.1007/s11739-023-03339-z
   PubMed Web of Science ®Google Scholar
• Iwaki M, Kobayashi T, Nogami A, et al. Impact of Sarcopenia on non-alcoholic fatty liver disease. Nutrients. 2023 Feb 10;15(4):891. doi: 10.3390/nu15040891
   PubMed Web of Science ®Google Scholar
• Habig G, Smaltz C, Halegoua-DeMarzio D. Presence and implications of Sarcopenia in Non-alcoholic Steatohepatitis. Metabolites. 2021 Apr 15;11(4):242. doi: 10.3390/metabo11040242
   PubMed Web of Science ®Google Scholar
• Caturano A, Acierno C, Nevola R, et al. Non-alcoholic fatty liver disease: from pathogenesis to clinical impact. Processes. 2021;9(1):135. doi: 10.3390/pr9010135
   Web of Science ®Google Scholar
• Rinaldi L, Pafundi PC, Galiero R, et al. Mechanisms of non-alcoholic fatty liver disease in the Metabolic Syndrome. A narrative review. Antioxidants. 2021; 10(2):270. doi: 10.3390/antiox10020270
   Web of Science ®Google Scholar
• Brunetti L, Kalabalik J Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies. P T 2012;37:687–696.
   PubMedGoogle Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases. Hepatology. 2018;67(1):328–357. doi: 10.1002/hep.29367
   PubMed Web of Science ®Google Scholar
• Mokhtare M, Abdi A, Sadeghian AM, et al. Investigation about the correlation between the severity of metabolic-associated fatty liver disease and adherence to the Mediterranean Diet. Clin Nutr ESPEN. 2023;58:221–227. doi: 10.1016/j.clnesp.2023.10.001
   PubMed Web of Science ®Google Scholar
• Vorobyeva VM, Vorobyeva IS, Morozov SV, et al. Specialized products for dietary correction of the diet of patients with non-alcoholic steatohepatitis. Vopr Pitan. 2021;90:100–109. doi: 10.33029/0042-8833-2021-90-2-100-109
   PubMedGoogle Scholar
• Ma Z, Chu L, Liu H, et al. Paeoniflorin alleviates non-alcoholic steatohepatitis in rats: involvement with the ROCK/NF-κB pathway. Int Immunopharmacol. 2016;38:377–384. doi: 10.1016/j.intimp.2016.06.023
   PubMed Web of Science ®Google Scholar
• Hasegawa T, Yoneda M, Nakamura K, et al. Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther. 2001;15:1667–1672. doi: 10.1046/j.1365-2036.2001.01083.x
   PubMed Web of Science ®Google Scholar
• Cortez-Pinto H, Jesus L, Barros H, et al. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr. 2006;25:816–823. doi: 10.1016/j.clnu.2006.01.027
   PubMed Web of Science ®Google Scholar
• Cuff DJ, Meneilly GS, Martin A, et al. Effective exercise modality to reduce insulin resistance in women with type 2 diabetes. Diabetes Care. 2003;26:2977–2982. doi: 10.2337/diacare.26.11.2977
   PubMed Web of Science ®Google Scholar
• Schwingshackl L, Missbach B, Dias S, et al. Impact of different training modalities on glycaemic control and blood lipids in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetologia. 2014;57:1789–1797. doi: 10.1007/s00125-014-3303-z
   PubMed Web of Science ®Google Scholar
• Oseini AM, Sanyal AJ. Therapies in non-alcoholic steatohepatitis (NASH). Liver Int. 2017;37(Suppl S1):97–103.
   PubMedGoogle Scholar
• Schneier AT, Citti CC, Dieterich DT. Management and diagnosis of fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:671–683. doi: 10.1586/17474124.2015.1003209
   PubMed Web of Science ®Google Scholar
• Adeghate E, Kalasz H, Veress G, et al. Medicinal chemistry of drugs used in diabetic cardiomyopathy. Curr Med Chem. 2010;17(6):517–551. doi: 10.2174/092986710790416281
   PubMed Web of Science ®Google Scholar
• Adeghate E, Mohsin S, Adi F, et al. An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical trials. Expert Opin Investig Drugs. 2019;28:811–820. doi: 10.1080/13543784.2019.1655539
   PubMed Web of Science ®Google Scholar
• Adeghate EA, Kalász H, Al Jaberi S, et al. Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development. Expert Opin Inv Drug. 2021;30:85–93. doi: 10.1080/13543784.2021.1865914
   PubMed Web of Science ®Google Scholar
• Verrastro O, Panunzi S, Castagneto-Gissey L, et al. Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet. 2023;401(10390):1786–1797. doi: 10.1016/S0140-6736(23)00634-7
   PubMed Web of Science ®Google Scholar
• Finelli C, Padula MC, Martelli G, et al. Could the improvement of obesity-related co-morbidities depend on modified gut hormones secretion? World J Gastroenterol. 2014 Nov 28;20(44):16649–16664. doi: 10.3748/wjg.v20.i44.16649
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Habener JF, Holst JJ. Discovery, characterization, and clinical development of the Glucagon-like Peptides. J Clin Invest. 2017;127:4217–4227. doi: 10.1172/JCI97233
   PubMed Web of Science ®Google Scholar
• Lotfy M, Singh J, Kalász H, et al. Medicinal chemistry and applications of incretins and DPP-4 inhibitors in the treatment of type 2 diabetes mellitus. Open Med Chem J. 2011;5(Suppl 2):82–92. doi: 10.2174/1874104501105010082
   PubMedGoogle Scholar
• Lotfy M, Singh J, Rashed H, et al. Mechanism of the beneficial and protective effects of exenatide in diabetic rats. J Endocrinol 2014, 220, 291–304. 3 10.1530/JOE-13-0426
   PubMed Web of Science ®Google Scholar
• Lotfy M, Singh J, Rashed H, et al. The Effect of Glucagon-like peptide-1 in the management of diabetes mellitus: cellular and molecular mechanisms. Cell Tissue Res. 2014;358(2):343–358. doi: 10.1007/s00441-014-1959-9
   PubMed Web of Science ®Google Scholar
• Wideman RD, Kieffer TJ. Mining incretin hormone pathways for novel therapies. Trends Endocrinol Metab. 2009;20:280–286. doi: 10.1016/j.tem.2009.02.005
   PubMed Web of Science ®Google Scholar
• Cao L, Li D, Feng P, et al. A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse Model of Parkinson’s disease by reducing chronic inflammation in the brain. Neuroreport. 2016;27:384–391. doi: 10.1097/WNR.0000000000000548
   PubMed Web of Science ®Google Scholar
• Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT. STEP 8 investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022 Jan 11;327(2):138–150. doi: 10.1001/jama.2021.23619
   PubMed Web of Science ®Google Scholar
• Taylor K, Gurney K, Han J, et al. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord. 2011 Apr 29;11:9. PMID: 21529363; PMCID: PMC3112417. doi: 10.1186/1472-6823-11-9
   PubMed Web of Science ®Google Scholar
• Guerci B, Giorgino F, Sapin H, et al. The Real-World Observational Prospective Study of Health Outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): patient disposition, clinical characteristics and treatment persistence at 12 months. Diab Obes Metab. 2022 Dec;24(12):2373–2382. Epub 2022 Aug 31. PMID: 35876235; PMCID: PMC9804517. doi: 10.1111/dom.14823
   PubMed Web of Science ®Google Scholar
• Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473–481. doi: 10.1016/S0140-6736(08)61246-5
   PubMed Web of Science ®Google Scholar
• Łuniewski M, Matyjaszek-Matuszek B, Lenart-Lipińska M Diagnosis and Non-Invasive Treatment of Obesity in adults with type 2 diabetes mellitus: a review of guidelines. J Clin Med. 2023;12(13):4431. doi: 10.3390/jcm12134431
   PubMed Web of Science ®Google Scholar
• Doumas M, Imprialos Κ, Stavropoulos K, et al. Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints. Curr Pharm Des. 2018;24(17):1879–1886. doi: 10.2174/1381612824666180604113653
   PubMed Web of Science ®Google Scholar
• Mahapatra MK, Karuppasamy M, Sahoo BM. Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: a narrative review. Pharm Res. 2022;39:1233–1248. doi: 10.1007/s11095-022-03302-1
   PubMed Web of Science ®Google Scholar
• Cariou B, Byrne CD, Loomba R, et al. Nonalcoholic fatty liver disease as a metabolic disease in Humans: a literature review. Diab Obes Metab. 2021;23:1069–1083. doi: 10.1111/dom.14322
   PubMed Web of Science ®Google Scholar
• Knudsen LB, Lau J. The discovery and development of Liraglutide and semaglutide. Front Endocrinol. 2019;10:155. doi: 10.3389/fendo.2019.00155
   PubMed Web of Science ®Google Scholar
• Barritt AS 4th, Marshman E, Noureddin M Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know. Aliment Pharmacol Ther. 2022;55:944–959, doi: 10.1111/apt.16794
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Hull D, Guo K, et al. Glucagon-like Peptide 1 Decreases Lipotoxicity in Non-Alcoholic Steatohepatitis. J Hepatol. 2016;64:399–408. doi: 10.1016/j.jhep.2015.08.038
   PubMed Web of Science ®Google Scholar
• Somm E, Montandon SA, Loizides-Mangold U, et al. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and Inflammatory Response in Mice Fed a methionine-choline deficient diet. Transl Res. 2021;227:75–88. doi: 10.1016/j.trsl.2020.07.008
   PubMed Web of Science ®Google Scholar
• Gu Y, Sun L, He Y, et al. Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials. Expert Rev Gastroenterol Hepatol. 2023 Mar;17(3):273–282. Epub 2023 Feb 6. PMID: 36689199. doi: 10.1080/17474124.2023.2172397
   PubMed Web of Science ®Google Scholar
• Hartman ML, Sanyal AJ, Loomba R, et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care. 2020 Jun;43(6):1352–1355. Epub 2020 Apr 14. PMID: 32291277; PMCID: PMC7245348. doi: 10.2337/dc19-1892
   PubMed Web of Science ®Google Scholar
• Boland ML, Laker RC, Mather K, et al. Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist cotadutide via modulating mitochondrial function and Lipogenesis. Nat Metab. 2020, 2(5):413–431, doi: 10.1038/s42255-020-0209-6
   PubMedGoogle Scholar
• Ayonrinde OT Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD – reconciling the present with the past. JHEP Rep 2021, 3, 100261, doi: 10.1016/j.jhepr.2021.100261
   PubMedGoogle Scholar
• Fernando DH, Forbes JM, Angus PW, et al. Development and progression of non-alcoholic fatty liver disease: the role of advanced glycation end products. Int J Mol Sci. 2019, 20, doi: 10.3390/ijms20205037
   Web of Science ®Google Scholar
• Wahlang B, Beier JI, Clair HB, et al. Toxicant-Associated Steatohepatitis. Toxicol Pathol. 2013;41:343–360. doi: 10.1177/0192623312468517
   PubMed Web of Science ®Google Scholar
• Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des. 2013;19:5219–5238. doi: 10.2174/13816128113199990381
   PubMed Web of Science ®Google Scholar
• Bashir A, Duseja A, De A, et al. Non-alcoholic fatty liver disease development: a multifactorial pathogenic phenomena. Liver res. 2022;6:72–83. doi: 10.1016/j.livres.2022.05.002
   Google Scholar
• Sakasai-Sakai A, Takeda K, Takeuchi M Involvement of intracellular TAGE and the TAGE–RAGE–ROS axis in the onset and progression of NAFLD/NASH. Antioxidants. 2023;12, 748. doi: 10.3390/antiox12030748
   Web of Science ®Google Scholar
• Sakasai-Sakai A, Takata T, Takeuchi M Intracellular toxic advanced glycation end-products promote the production of reactive oxygen species in HepG2 cells. Int J Mol Sci. 2020;21, doi: 10.3390/ijms21144861
   PubMed Web of Science ®Google Scholar
• Brunner KT, Henneberg CJ, Wilechansky RM, et al. Nonalcoholic fatty liver disease and obesity treatment. Curr Obes Rep. 2019;8:220–228. doi: 10.1007/s13679-019-00345-1
   PubMed Web of Science ®Google Scholar
• Patel NS, Doycheva I, Peterson MR, et al. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2015;13:561–568.e1. doi: 10.1016/j.cgh.2014.08.039
   PubMed Web of Science ®Google Scholar
• Bułdak Ł, Machnik G, Skudrzyk E, et al. The impact of exenatide (a GLP-1 agonist) on markers of inflammation and oxidative stress in normal human astrocytes subjected to various glycemic conditions. Exp Ther Med. 2019;17:2861–2869. doi: 10.3892/etm.2019.7245
   PubMed Web of Science ®Google Scholar
• Wang Y, Parlevliet ET, Geerling JJ, et al. Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. Br J Pharmacol. 2014;171:723–734. doi: 10.1111/bph.12490
   PubMed Web of Science ®Google Scholar
• Wang X-C, Gusdon AM, Liu H, et al. Effects of glucagon-like peptide-1 receptor agonists on Non-Alcoholic Fatty liver disease and inflammation. World J Gastroenterol. 2014;20:14821–14830. doi: 10.3748/wjg.v20.i40.14821
   PubMed Web of Science ®Google Scholar
• Ao N, Yang J, Wang X, et al. Glucagon-like peptide-1 preserves non-alcoholic fatty liver disease through inhibition of the Endoplasmic Reticulum Stress-Associated Pathway. Hepatol Res. 2016;46:343–353. doi: 10.1111/hepr.12551
   PubMed Web of Science ®Google Scholar
• Eguchi Y, Kitajima Y, Hyogo H, et al. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res. 2015;45:269–278. doi: 10.1111/hepr.12351
   PubMed Web of Science ®Google Scholar
• Melander SA, Kayed A, Andreassen KV, et al. OXM-104, a potential Candidate for the Treatment of Obesity, NASH and type 2 diabetes. Eur J Pharmacol. 2024;962:176215. doi: 10.1016/j.ejphar.2023.176215
   PubMed Web of Science ®Google Scholar
• Nahra R, Wang T, Gadde KM, et al. Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study. Diabetes Care. 2021;44:1433–1442. doi: 10.2337/dc20-2151
   PubMed Web of Science ®Google Scholar
• Parker VER, Robertson D, Erazo-Tapia E, et al. Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes. Nat Metab 2023;5:2086–2093. doi: 10.1038/s42255-023-00938-0
   PubMedGoogle Scholar
• Marcondes-de-Castro IA, Oliveira TF, Spezani R, et al. Cotadutide effect in liver and adipose tissue in obese mice. J Mol Endocrinol. 2023;70:e220168. doi: 10.1530/JME-22-0168
   PubMed Web of Science ®Google Scholar
• Nevola R, Epifani R, Imbriani S, et al. GLP-1 receptor agonists in Non-Alcoholic Fatty liver disease: Current evidence and future perspectives. Int J Mol Sci. 2023 Jan 15;24(2):1703. doi: 10.3390/ijms24021703
   PubMed Web of Science ®Google Scholar